De novo MET amplification promotes intrinsic resistance to first-generation EGFR tyrosine kinase inhibitors

Gelijkaardige items

• MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors
  door: Kubo, Takafumi, et al.
  Gepubliceerd in: (2009)
• Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors
  door: Westover, D, et al.
  Gepubliceerd in: (2018)
• A case of EGFR mutant lung adenocarcinoma that acquired resistance to EGFR-tyrosine kinase inhibitors with MET amplification and epithelial-to-mesenchymal transition
  door: Miyoshi, Seigo, et al.
  Gepubliceerd in: (2015)
• Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line
  door: Sullivan, Ivana, et al.
  Gepubliceerd in: (2017)
• Update on third-generation EGFR tyrosine kinase inhibitors
  door: Gray, Jhanelle, et al.
  Gepubliceerd in: (2014)